FCM
INSY

Freshford Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Freshford Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-452,600
Closed -$16.3M – 29
2015
Q2 		$16.3M Buy
+452,600
New +$14.1M 2.58% 16

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freshford Capital Management's INSY Position: Q4 2016 in Review

Freshford Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2016, closing a stake of 382,283 shares — an estimated $4.51M sold.

Freshford Capital Management first reported a position in INSY in Q2 2016 and held it in 2 quarters. The position peaked at $6.16M in Q2 2016. 138 funds tracked by Wall St. Rank hold INSY as of Q4 2016.

  • Freshford Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Freshford Capital Management sold 382,283 Insys Therapeutics, Inc. shares in Q4 2016, an estimated $4.51M.
  • Freshford Capital Management first reported a position in Insys Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Freshford Capital Management's Insys Therapeutics, Inc. position peaked at $6.16M in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2016.

Based on Freshford Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.